Globus Medical, Inc. GMED
74.52
0.25
0.34%
as of 25 Sep
- Market cap
- $10.0B
- P/E
- 18.8×
Follow GMED
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
18.36 | 21.94 | 19.81 | 19.90 |
P/S ratio |
2.78 | 4.02 | 3.76 | 3.39 | |
P/FCF ratio |
13.76 | 20.75 | 19.75 | 14.50 | |
P/Operating CF |
30.85 | 47.49 | 57.63 | 50.88 | |
P/B ratio |
1.75 | 2.58 | 2.46 | 2.24 | |
Price to Tangible BV |
3.52 | 4.93 | 4.53 | 4.05 | |
EV/Sales |
2.95 | 4.12 | 3.84 | 3.48 | |
EV/EBITDA |
11.36 | 15.47 | 14.27 | 11.72 | |
EV/Operating CF |
11.43 | 16.07 | 15.28 | 12.01 | |
EV/FCF |
14.60 | 21.28 | 20.14 | 14.86 | |
Quick Ratio |
2.31 | 2.61 | 2.83 | 2.78 | |
Current Ratio |
4.13 | 4.26 | 4.56 | 4.62 | |
Net Debt/EBITDA |
(1.81) | (2.27) | (2.86) | (2.36) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.54 | 0.56 | 0.61 | 0.60 | |
Operating CF/Net income |
2.10 | 1.77 | 1.63 | 1.38 | |
Capex/Depreciation |
(0.58) | (0.61) | (0.57) | (0.48) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4.95% | 4.38% | 4.80% | 4.60% | |
Selling, General and Administrative Expense of Revenue |
40.78% | 38.54% | 39.19% | 36.32% | |
Intangible Assets out of Total Assets |
0.43 | 0.41 | 0.40 | 0.39 | |
Share Based Compensation of Revenue |
1.50% | 1.38% | 1.66% | 1.69% | |
Graham Net Nets |
0.16 | 0.12 | 0.13 | 0.14 | |
Graham Number |
47.92 | 55.03 | 58.50 | 56.16 | |
Earnings Yield |
5.45% | 4.56% | 5.05% | 5.02% | |
Free Cash Flow Yield |
7.27% | 4.82% | 5.06% | 6.90% | |
Revenue per Share |
5.72 | 6.11 | 5.61 | 5.85 | |
Operating CF per Share |
1.86 | 1.84 | 1.50 | 1.55 | |
Capex per Share |
(0.34) | (0.34) | (0.29) | (0.25) | |
Free Cash Flow per Share |
1.52 | 1.50 | 1.20 | 1.31 | |
Cash per Share |
2.90 | 4.12 | 4.65 | 4.41 | |
Shareholders Equity per Share |
32.70 | 33.82 | 34.96 | 35.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
32.70 | 33.82 | 34.96 | 35.31 | |
Free Cash Flow |
204.21 | 202.31 | 162.75 | 176.57 | |
Working Capital |
1,458.40 | 1,627.11 | 1,715.66 | 1,736.17 | |
Capital Expenditures |
(45.48) | (46.28) | (39.61) | (33.17) | |
Net Current Asset Value |
1,227.55 | 1,396.10 | 1,490.88 | 1,495.86 | |
EV/EBIT |
22.04 | 25.24 | 22.31 | 17.10 | |
Capex to Sales |
0.06 | 0.06 | 0.05 | 0.04 | |
Net Profit Margin |
15.47% | 17.01% | 16.36% | 19.20% | |
Price to Operating Income |
20.78 | 24.60 | 21.87 | 16.69 | |
| Other line items | |||||
Average Receivables |
640.66 | 661.00 | 636.78 | 699.70 | |
Average Payables |
72.38 | 86.99 | 88.40 | 97.02 | |
Average Inventory |
744.62 | 709.26 | 718.10 | 791.51 | |
Average Assets |
5,090.84 | 5,277.26 | 5,075.35 | 5,224.67 | |
Average Common Equity |
4,234.11 | 4,375.29 | 4,410.19 | 4,532.14 |
Columns are period end dates